• Reference Citation Analysis
  • v
  • v
  • Find an Article
  • Find an Author
Download
Number Citation Analysis
1
Feng L, Mi G, Shi X, You M, Yang J, Qin G, Sun G, Chen Q. Tough Interfacial Adhesion Enabled Extremely Durable Flexible Supercapacitors. ACS Appl Mater Interfaces 2023;15:53951-53964. [PMID: 37960858 DOI: 10.1021/acsami.3c12784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2023]
2
Liu W, Li L, Mi G, Wang J, Pan Y. Effect of Fe Content on Microstructure and Properties of Laser Cladding Inconel 625 Alloy. Materials (Basel) 2022;15:ma15228200. [PMID: 36431684 PMCID: PMC9693548 DOI: 10.3390/ma15228200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 11/02/2022] [Accepted: 11/03/2022] [Indexed: 05/14/2023]
3
Machado-Paula MM, Corat MAF, Lancellotti M, Mi G, Marciano FR, Vega ML, Hidalgo AA, Webster TJ, Lobo AO. A comparison between electrospinning and rotary-jet spinning to produce PCL fibers with low bacteria colonization. Mater Sci Eng C Mater Biol Appl 2020;111:110706. [PMID: 32279777 DOI: 10.1016/j.msec.2020.110706] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 01/07/2020] [Accepted: 01/28/2020] [Indexed: 12/18/2022]
4
Herbst R, Arkenau H, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Chao B, Ferry D, Mi G, Paz-Ares L. MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.615] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
5
Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Tourneau CL, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz157.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
6
Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Jin J, Mi G, Rege J, Paz-Ares L. Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx091.010] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
7
Reck M, Bang YJ, Goff L, Wasserstrom H, Yang J, Mi G, Karasarides M. Multizentrische, offene Phase 1 Studie mit Ramucirumab plus Durvalumab bei Patienten mit inoperablem lokal fortgeschrittenen oder metastasierten Adenokarzinom des Magens oder gastrooesophagealen Übergangs (G/GEJ), nichtkleinzelligem Lungenkarzinom (NCSLC) oder hepatozellulärem Karzinom (HCC). Pneumologie 2017. [DOI: 10.1055/s-0037-1598341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
8
Chung H, Chao Y, Lee KW, Kudo M, Yen CJ, Kim T, Yamazaki K, Shih JY, Kim SW, Sohn JH, Cheng R, Zhang Y, Binder P, Mi G, Orlando M, Muro K. 153P Ramucirumab safety in East Asian (EA) compared to non-EA patients: A meta-analysis of adverse events (AEs) in 6 global, randomized, double-blind, phase 3 clinical trials. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw579.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]  Open
9
Lin CC, Golan T, Corral J, Moreno V, Chung H, Wasserstrom H, Yang J, Mi G, Bang YJ. Phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastrointestinal or thoracic malignancies (NCT02572687); Phase 1a results. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw525.01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]  Open
10
Bang YJ, Goff L, Wasserstrom H, Yang J, Mi G, Karasarides M, Reck M. An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma (HCC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw378.53] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]  Open
11
Herbst R, Martin-Liberal J, Calvo E, Isambert N, Bendell J, Cassier P, Perez-Gracia J, Yang J, Rege J, Mi G, Ferry D, Paz-Ares L. Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.34] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
12
Jian J, Li C, Xu J, Qiao D, Mi G, Chen X, Tang M. Associations of serotonin receptor gene HTR3A, HTR3B, and HTR3A haplotypes with bipolar disorder in Chinese patients. Genet Mol Res 2016;15:gmr8671. [PMID: 27706728 DOI: 10.4238/gmr.15038671] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
13
Shao W, Zhang L, Wang C, Mi G. [Studies of the determination of glycyrrhizin acid kali salt by HPLC and the pharmacokinetics]. Zhong Yao Cai 2001;24:584-5. [PMID: 11715198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
14
Shao W, Wang D, Mi G, Wang C. [Study of the inclusion compound of rutin with beta-cyclodextrin]. Zhong Yao Cai 1998;21:31-3. [PMID: 12567968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA